Posted inGastroenterology Nephrology news
OCE-205 Signals a Potential New Direction for Hepatorenal Syndrome-AKI, with Tolerability at the Center
In a phase 2 randomized trial, OCE-205 improved HRS-AKI in more patients than placebo and showed no excess ischemic or respiratory toxicity, but the study was underpowered after early termination.